The International Society for Cell & Gene Therapy (ISCT) has filed an amicus curiae brief to support the U.S. government's appeal in U.S.A. v. California Stem Cell Treatment Center, Inc., a case that ruled against the Food and Drug Administration (FDA) regulation of stromal vascular fraction...
The International Society for Cell and Gene Therapy MSC Committee Publishes its Perspectives on ISO/TS22859:2022 and ISO24651:2022 with Details of their Extensive Input in the Development of these International Standards. Dr. Mikey Creane, PhD Regenerative Medicine Institute...
ISCT issues response to US federal judge ruling on FDA regulation of cell and gene therapies US federal judge ruling of significant concern, with widespread implications for cell and gene therapy sector as well as patient safety Vancouver, Canada, September 12, 2022 - ...
ISCT addresses manufacturing standardization, a critical issue constraining the CGT development pipeline Key insights published from ISCT 2022 Commercialization Signature Series Vancouver, Canada, September 8, 2022 - The International Society for Cell & Gene Therapy (ISCT...
ISCT & CMaT to roll out additional training programs following successful global launch of 'Workforce Development in Biomanufacturing' course The collaboration seeks to address the critical skilled labor shortage in the cell and gene therapy industry. Vancouver, Canada,...
ISCT announces recipients of key 2022 achievement awards in cell and gene therapy Vancouver, Canada, April 07, 2022 - The International Society for Cell & Gene Therapy (ISCT) , the global society of clinicians, researchers,...
ISCT completes focus and program for 2022 Annual Meeting in San Francisco to cover cell and gene therapy ‘ Bench to Bedside to Benefit’ Annual Meeting to provide venue for the entire cell and gene therapy sector to generate solutions to its major barriers of providing therapies...